Contents

Aplindore

Chemical compound

Aplindore

Clinical data
ATC code	none
Identifiers
IUPAC name (2S)-2-[(phenylmethylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[3,2-e]indol-8-one
CAS Number	189681-70-7 Y fumarate: 189681-71-8 Y
PubChem CID	6440763
ChemSpider	139676 Y
UNII	Q5O76TA0ML fumarate: P13TV5A758 Y
KEGG	D03214 Y
ChEMBL	ChEMBL2110659 N
CompTox Dashboard (EPA)	DTXSID60870185
Chemical and physical data
Formula	C18H18N2O3
Molar mass	310.353 g·mol−1
3D model (JSmol)	Interactive image
SMILES c4ccccc4CNCC(CO2)Oc1c2ccc(N3)c1CC3=O
InChI InChI=1S/C18H18N2O3/c21-17-8-14-15(20-17)6-7-16-18(14)23-13(11-22-16)10-19-9-12-4-2-1-3-5-12/h1-7,13,19H,8-11H2,(H,20,21)/t13-/m0/s1 Y Key:DYJIKHYBKVODAC-ZDUSSCGKSA-N Y
NY (what is this?)  (verify)

Aplindore (DAB-452) is a drug which acts as a partial agonist selective for the dopamine receptor D2.^[1] It is being developed by the pharmaceutical company Neurogen as a treatment for Parkinson's disease and restless legs syndrome.

On December 23, 2009 Neurogen was acquired by Ligand Pharmaceuticals. Rights to Aplindore were given to Ligand around time of merger. As of 2008, Phase II was completed and Ligand.

Upon reviewing company website (Ligand.com) this drug is currently not listed at the moment due to several programs already partnered with GSK. GSK holds a significant share of the drug RLS drug programs on the market with Requip XR and the recent FDA approval of Horizant. To prevent any direct competition and losing strong ties with GSK, Aplindore is not listed at the moment on Lidgand website. If this medication were to reach phase III, this could adversely effect Ligand`s portfolio of partnered and unpartnered assets. By electing not to list the drug on company website, Ligand maintains the appearance that they are "currently actively seeking a partner" when a potential investor inquirers about drug development via email.

References[edit]